Qinprezo vosaroxin: Phase I data

Data from 13 patients with MDS in an open-label, U.S. Phase I trial showed that the MTD of IV Qinprezo on days 1 and 4 of a 28-day cycle plus azacitidine for <=6 cycles was 34 mg/m 2. At the initial dose of 50 mg/m 2 Qinprezo, there were 2 DLTs of grade 4 hyperbilirubinemia and neutropenia. In 12 evaluable patients, the combination led to 3 marrow complete remissions (mCRs), 1 mCR with erythroid improvement, 1 mCR with neutrophil improvement, 2 mCRs with platelet improvement and 1 mCR with neutrophil and platelet improvement, plus 4 cases of stable disease. The trial was sponsored by Washington University School of Medicine. Next month, data will be presented at the American Society of Hematology meeting in Orlando. ...